Regenxbio (RGNX) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
REGENXBIO Reports First Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD
May 7, 2019 4:06 PM EDTROCKVILLE, Md., May 7, 2019 /PRNewswire/ --
Reports positive interim update from RGX-314 Phase I/IIa trial for wet AMD in Cohort 3 over one year Announces new IND submission for RGX-314 for a Phase II trial in diabetic retinopathy; filing planned for second half 2019Â Continuing subject recruitment for RGX-121 Phase I/II trial for MPS II, RGX-111 Phase I trial for MPS I and RGX-501 Phase I/II trial for HoFH; interim updates for all trials expected in second half 2019 On-track to submit IND for... More